Semaglutide 2.4mg Weekly Shows Promise for Adolescent Weight Management
A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity
Background
The global prevalence of obesity and overweight among adolescents is a growing public health crisis, contributing to significant long-term health complications. Despite the urgent need, effective and safe pharmacological interventions specifically tailored for this younger demographic remain limited. This randomized, placebo-controlled trial directly addresses this gap by investigating the efficacy and safety of semaglutide 2.4 mg once weekly in adolescents with overweight or obesity.
TitrateLab articles covering Semaglutide
Written by TitrateLab, separately from the study summarized above.
